This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Sep 9;385(11):1055-1056.

doi: 10.1056/NEJMc2111763.

Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris

Zachary H Hopkins¹, Benedict C Wu¹, Carlos H Nousari¹

Affiliations

PMID: 34496187
DOI: 10.1056/NEJMc2111763

Comment

Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris

Zachary H Hopkins et al. N Engl J Med. 2021.

. 2021 Sep 9;385(11):1055-1056.

doi: 10.1056/NEJMc2111763.

Authors

Zachary H Hopkins¹, Benedict C Wu¹, Carlos H Nousari¹

Affiliation

¹ Broward Health Medical Center, Fort Lauderdale, FL zhhopkins@browardhealth.org.

PMID: 34496187
DOI: 10.1056/NEJMc2111763

No abstract available

PubMed Disclaimer

Comment in

Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris. Reply.
Werth VP, Joly P, Chen DM. Werth VP, et al. N Engl J Med. 2021 Sep 9;385(11):1056. doi: 10.1056/NEJMc2111763. N Engl J Med. 2021. PMID: 34496188 No abstract available.

Comment on

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, Gearhart L, Kapre A, Pordeli P, Chen DM; PEMPHIX Study Group. Werth VP, et al. N Engl J Med. 2021 Jun 17;384(24):2295-2305. doi: 10.1056/NEJMoa2028564. Epub 2021 May 19. N Engl J Med. 2021. PMID: 34097368 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information